TrialClinical breast cancer2016

Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.

Marissa D Friedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.